Melinda Decker is the Chief Commercial Officer for Mymee, a JLabs Digital Therapeutics company working in autoimmune disease. She is a global biopharmaceutical and digital health leader with a mix of commercial and R&D expertise. She has been a digital health consultant and also served as an advisor to MIT’s Health Science & Technology program, and to HealthMode, focused on AI-enabled clinical trials and validating new digital biomarkers. Previously, Melinda was the Oncology & Diabetes TA Head for AstraZeneca’s Digital Health team. She holds an MS in Biochemical Engineering and an MBA in Finance and Marketing.